Organon announced on March 31, 2025, that it has acquired the regulatory and commercial rights in the U.S. for TOFIDENCE (tocilizumab-bavi) from Biogen Inc. TOFIDENCE is a biosimilar to ACTEMRA (tocilizumab) for intravenous infusion.
TOFIDENCE, which launched in May 2024, is the first approved tocilizumab biosimilar entrant in the U.S. market. It is indicated for the treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19.
This acquisition strengthens and expands Organon's U.S. biosimilars immunology portfolio. Organon will make an upfront payment to Biogen and assume the obligation to pay tiered royalty and annual net sales milestone payments to Bio-Thera Solutions Ltd., the product developer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.